TM Substanzbibliotheken

The Diversity Core Library Part 1 comprises over 50,000 compounds selected from a pool of 1.6 million compounds. This collection emphasizes the diversity of compound structures obtained after filtering out PAINS, REOS and MedChem filters.

The unparalleled chemical diversity of natural products makes them an ideal choice for screening active small molecules. Natural products is always a significant source in drug discovery. According to authoritative statistics, 79 out of 99 small molecule anticancer drugs have been successfully developed based on natural products since 1981._x000D_ _x000D_ Natural products have demonstrated successful modulation of isolated but crucial targets, especially in antimicrobial targets and protein interactions. Many researchers consider natural products and their derivatives as unique tools for studying and manipulating protein function._x000D_ _x000D_ The Drug-like Natural Compound Library comprises 522 novel molecules, serving as a complement to the L6000 Natural Product Library. This library enhances the probability of successful drug screening, making it an excellent tool for lead compound discovery.

The library offers a solution for establishing a foundation in the early stages of constructing a large screening library due to its large-scale supply and high cost-effectiveness. This foundation supports subsequent drug-like screening and cutting-edge research involving multiple targets and pathways.

<p>A unique collection of 2808 approved drugs for high throughput screening (HTS) and high content screening (HCS);</p>

<p>3158 compounds from marketed drugs for high throughput screening (HTS) and high content screening (HCS);</p>

A unique collection of xnum EMA-approved drugs for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 343 protease and proteasome inhibitors for research in chemical genomics, and drug screening;

<p>A unique collection of xnum microtubule-targeted compounds can be used in HTS and HCS;</p>

<p>xnum well-chosen unique AMPK-targeted small molecules；</p>

Well-chosen 953 compounds related to epigenetic regulation for research in epigenetics, high throughput screening (HTS) and high content screening (HCS) for new

<p>A unique collection of 420 compounds targeting PI3K/Akt/mTOR signaling for research in PI3K/Akt/mTOR signaling, and drug discovery in diseases involved with</p>

<p>A unique collection of 759 cytoskeleton-related compounds, can be used for HTS and HCS；</p>

Well-chosen xnum compounds with unique structures targeting transcription factor;

A unique collection of 365 compounds targeting MAPK signaling for drug discovery in MAPK related diseases;

<p>A unique collection of xnum GPCR-active agents for high throughput screening and high content screening for GPCR drug discovery, and new GPCR target</p>

<p>A unique collection of 531 nuclear receptor signaling targeted compounds for high throughput and high content screening;</p>

<p>A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;</p>

<p>A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.</p>

<p>Contains xnum active small molecules for research related to post-translational modifications (PTMs);</p>

<p>A unique collection of 1040 anti-virus compounds effective for new anti-virus drugs high throughput screening and high content screening;</p>

A unique collection of 1133 compounds with confirmed anti-SARS-CoV-2 activity or potential activity and part of them are broad-spectrum antiviral agents；

<p>A unique collection of xnum nucleoside and nucleotide analogues, can be used for research and development of anti-viral, anti-tumor, anti-fungal, and anti-</p>

A unique collection of xnum anti-infective compounds including anti-bacterial, anti-fungi, anti-Human Cytomegalovirus (HCMV), anti-HIV, anti-SARS, anti-

<p>A unique collection of xnum diabetes related compounds;</p>

<p>A unique collection of 8328 inhibitors for research in cell signaling, high throughput screening (HTS) and high content screening (HCS) for new drugs;</p>

<p>A unique collection of xnum compounds with anti-cancer activity for high throughput screening (HTS) and high content screening (HCS);</p>

<p>A unique collection of 1779 approved anti-cancer drugs for high throughput screening (HTS) and high content screening (HCS);</p>

<p>A unique collection of 2545 anti-cancer compounds for high throughput screening (HTS) and high content screening (HCS);</p>

<p>A unique collection of 1268 cancer cellular metabolism related compounds for cancer research and high throughput screening (HTS) and high content screening (HCS</p>

<p>A unique collection of 406 cancer cell differentiation inducing compounds for high throughput and high content screening;</p>

<p>A unique collection of 3080 anticancer drugs for high throughput screening (HTS) and high content screening (HCS);</p>

48 Chemotherapeutic drugs that can be used for high-throughput and high-content screening.

<p>xnum tumor-targeted drugs that can be used for high-throughput and high-content screening.</p>

<p>A unique collection of 3188 compounds with known anti-cancer activity for high throughput screening (HTS) and high content screening (HCS);</p>

<p>A unique collection of 449 compounds acting on immune-oncology therapeutic targets can be used for high throughput and high content screening；</p>

<p>A unique collection of 1702 compounds with anti-lung cancer therapeutic activity or targeting lung cancer’s major signaling pathways, can be used for anti-lung</p>

A unique collection of 1939 compounds with anti-breast cancer therapeutic activity or targeting breast cancer’s major signaling pathways, can be used for anti-

<p>A unique collection of 2238 pancreatic cancer related compounds can be used in HTS and HCS;</p>

<p>xnum species of compounds related to liver cancer that can be used in anti-liver cancer drug development and pharmacological studies.</p>

xnum compounds associated with colorectal cancer that can be used for high-throughput and high-content screening.

<p>2070 compounds associated with prostate cancer that can be used for high-throughput and high-content screening.</p>

<p>A unique collection of xnum compounds with anti-ovarian cancer therapeutic activity, can be used for anti-ovarian cancer drug discovery and pharmacological</p>

<p>A unique collection of 1016 tyrosine kinase inhibitors for high throughput screening and high content screening for drug discovery in tyrosine kinase related</p>

<p>A unique collection of 931 compounds targeting ion channels for research in ion channels-related diseases and ion channel drug discovery;</p>

<p>A unique collection of 784 compounds targeting endocrine system for high throughput screening (HTS) and high content screening (HCS) for new drugs;</p>

<p>A collection of xnum selected human endogenous metabolites for high throughput and high content screening.</p>

A unique collection of xnum endogenous metabolism-related compounds for research in endogenous metabolism-related diseases and drug screening.

<p>The TargetMol Bile Acids Compound Library carefully curates an xnum number of natural primary and secondary bile acids.</p>

<p>A unique collection of 492 compounds targeting lipid metabolism, can be used for high-throughput screening (HTS) and high-content screening (HCS).</p>

<p>xnum glycometabolism-related comounds, can be used for HTS and HCT;</p>

<p>555 glycolysis-related active compounds for high-throughput and high-content screening.</p>

A unique collection of xnum mouse metabolites, which can be used for HTS and HCS;

<p>A unique collection of 614 gut microbial metabolites which can be used for HTS and HCS;</p>

<p>A unique collection of xnum glutamine metabolism related compounds can be used for high throughput screening (HTS) and high content screening (HCS), and also is</p>

A unique collection of xnum metabolic pathway-related bioactive small molecule compounds for high-throughput, high-content screening.

<p>A unique collection of 4454 human metabolites for high-throughput, high-content screening.</p>

A unique collection of xnum compounds targeting CNS signaling for high throughput screening (HTS) and high content screening (HCS) for new drugs;

<p>A unique collection of 1513 neurotransmitter receptor compounds, can be used for HTS and HCS screening；</p>

A unique collection of xnum compounds related to neurodegenerative diseases can be used for HTS or HCS；

<p>xnum compounds related to neuronal differentiation, suitable for the drug development of nervous system disease.</p>

<p>A unique collection of xnum bioactive small molecules with neuroprotective relevance for high throughput screening (HTS) and high content screening (HCS);</p>

A unique collection of xnum pain-related compounds for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 193 bioactive compounds specifically targeting adrenergic receptors, effective tool for screening new drugs or new target identification;

A unique collection of xnum compounds targeting serotonin receptors for high throughput screening and high content screening;

<p>1264 small molecule compounds with pro-oxidant or anti-oxidant activity for high-throughput and high-content screening.</p>

Oxidative stress reflects an imbalance between the systemic manifestation of reactive oxygen species (ROS) and a biological system&#039;s ability to readily detoxify

<p>A unique collection of 101 compounds with defined hematopoietic toxicity for high throughput and high content drug screening;</p>

<p>A unique collection of 1248 compounds with defined autophagy-inducing or -inhibitory activity for research in autophagy, high throughput screening (HTS) and</p>

<p>A unique collection of xnum compounds targeting histaminergic receptor and melatonin receptor for high throughput screening (HTS) and high content screening (HCS</p>

A unique collection of 3404 compounds in clinical trial phases for high throughput screening (HTS) and high content screening (HCS);

<p>A unique collection of 701 preclinical compounds for high throughput screening (HTS) and high content screening (HCS);</p>

A unique collection of xnum histone modification related compounds for high throughput screening (HTS) and high content screening (HCS);

<p>xnum methylation-related compounds that can be used for high-throughput and high-content screening.</p>

<p>A unique collection of xnum compounds targeting cytokine signaling for high throughput screening and high content screening for drug discovery;</p>

<p>A unique collection of 252 JAK/STAT signaling targeted compounds for high throughput and high content screening;</p>

A unique collection of xnum compounds targeting NF-κB signaling for high throughput screening and high content screening;

<p>A unique collection of xnum DNA Damage &amp;amp; Repair related compounds for high throughput screening (HTS) and high content screening (HCS);</p>

<p>Offers xnum small molecules that enhance gene editing efficiency, suitable for high-throughput screening (HTS) and high-content screening (HCS);</p>

<p>A collection of 14439 small molecule compounds with validated activity for high throughput screening (HTS), high content screening (HCS), cell induction, and</p>

A collection of xnum bioactive compounds for high-throughput screening, high-content screening, cell induction and target identification.

<p>TargetMol created the L4020 NO-PAINS Compound Library that applied the PAINS filter, remaining 9384 small molecules that are suitable for new drug development,</p>

<p>A unique collection of xnum TGF-beta/Smad signaling targeted compounds for high throughput and high content screening;</p>

<p>It is well-selected from Bioactive compound library Plus (D7800), from which 1-15 compounds with the highest scores (activity value, pharmacological properties</p>

<p>A unique collection of 1729 FDA approved drugs for high throughput screening (HTS) and high content screening (HCS);</p>

<p>A unique collection of 237 Wnt/Hedgehog/Notch signaling targeted compounds for high throughput and high content screening;</p>

<p>A unique collection of xnum compounds with antibiotic activity for new antibacterial drug screening;</p>

<p>A unique collection of 252 antifungal compounds effective for drug repurposing screening, combination screening and biological investigation.</p>

419 well-chosen unique anti-parasitic small molecules;

A unique collection of 904 antibacterial bioactive compounds, a powerful tool for antibacterial drug development;

<p>Contains xnum types of compounds with activity against Gram-negative bacteria, suitable for high-throughput and high-content screening;</p>

<p>A unqie collection of xnum anti gram-positive bacteria compounds for high throughput screening (HTS) and high content screening (HCS);</p>

A unique collection of 3048 plant-sourced compounds that derived from 277 plant species for high throughput screening (HTS) and high content screening (HCS);

<p>A unique collection of xnum anti-inflammation compounds effective for high throughput screening and high content screening.</p>

<p>xnum non-steroidal anti-inflammatory compounds for high-throughput and high-content screening.</p>

<p>A unique collection of 1353 proangiogenic and antiangiogenic compounds for new targets identification, research in mechanisms of angiogenesis, and high</p>

A unique collection of 131 cardiotoxicity inducing compounds for toxicological study;

<p>A unique collection of 574 fluorochemicals that can be used for high through-put screening (HTS) and high content screening (HCS);</p>

<p>A unique collection of 1544 metabolism diseases related compounds for high throughput screening (HTS) and high content screening (HCS);</p>